万维提示：
1、投稿方式：在线投稿。
2、期刊网址：https://www.springer.com/journal/12282
3、投稿网址：https://www.editorialmanager.com/brca
4、官网邮箱：相关咨询邮箱如下。
5、期刊刊期：双月刊，逢单月出版。
2021年6月4日星期五
期刊相关咨询邮箱【官网信息】
Contact the journal
Submission-related enquiries
Queries about submission issues, peer review process, or the status of your manuscript should be sent to Janani Sargunam (Janani.Sargunam@springernature.com).
Publication-related enquiries
Queries about accepted manuscripts in production or post-publication corrections should be sent to Saravanan Babu (Saravanan.Babu@springer.com).
Other editorial enquiries
Any other queries about the journal or presubmission enquiries should be sent to Yoko Arai (yoko.arai@springer.com).
投稿须知【官网信息】
Submission guidelines
Instructions for authors
The editors of Breast Cancer abide by the recommendations formulated by the International Committee of Medical Journal Editors (ICMJE) ( http://www.icmje.org/ ).
Aims and scope
Breast Cancer, the official journal of the Japanese Breast Cancer Society, publishes articles that contribute to progress in the field, in basic or translational research and also in clinical research, seeking to develop a new focus and new perspectives for all who are concerned with breast cancer. The journal welcomes all original articles describing clinical and epidemiological studies and laboratory investigations regarding breast cancer and related diseases. The journal will consider five types of articles: editorials, review articles, original articles, case reports, and rapid communications. Although editorials and review articles will principally be solicited by the editors, they can also be submitted for peer review, as in the case of original articles. The journal provides the best of up-to-date information on breast cancer, presenting readers with high-impact, original work focusing on pivotal issues.
All papers, which must be written in English, will be subject to review, and the quality of the English text will be thoroughly reviewed. Manuscripts submitted to the journal must not have been published or submitted elsewhere in substantially similar form or content, nor can they be submitted elsewhere during the processing for publication by Breast Cancer. Copyright of articles published in Breast Cancer is owned by the Japanese Breast Cancer Society.
Its publication must be approved by all co-authors, if any, as well as by the responsible authorities – tacitly or explicitly – at the institute where the work has been carried out.
Before submitting work for publication, authors whose first language is not English should seek the assistance of a colleague who is a native speaker of English and is familiar with the field of work.
Although the editors and referees make every effort to ensure the scientific accuracy of published manuscripts, the final responsibility rests with authors, not with the journal, its editors, the society, or the publisher.
Clinical trial registration
Breast Cancer adopts ICMJE's policy regarding clinical trial registration (http://www.icmje.org/recommendations/browse/publishing-and-editorial-issues/clinical-trial-registration.html). Specifically, Breast Cancer requires registration of clinical trials in a public trials registry at or before the time of first patient enrollment as a condition of consideration for publication.
Breast Cancer follows the International Committee of Medical Journal Editors (ICMJE), which uses the World Health Organization's definition of a clinical trial. The ICMJE defines a clinical trial as "Any research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.' Health-related interventions include any intervention used to modify a biomedical or health-related outcome (for example, drugs, surgical procedures, devices, behavioral treatments, dietary interventions, and process-of-care changes). Health outcomes include any biomedical or health-related measures obtained in patients or participants, including pharmacokinetic measures and adverse events. Purely observational studies (those in which the assignment of the medical intervention is not at the discretion of the investigator) will not require registration."
The ICMJE lists the following registries as fully compliant:
Australian New Zealand Clinical Trials Registry
ClinicalTrials.gov
ISRCTN Register
UMIN Clinical Trials Registry
Netherlands Trial Register
Brazilian Clinical Trials Registry (ReBec)
Chinese Clinical Trial Registry (ChiCTR)
Clinical Research Information Service (CRiS), Republic of Korea
Clinical Trials Registry - India (CTRI)
Cuban Public Registry of Clinical Trials(RPCEC)
EU Clinical Trials Register (EU-CTR)
German Clinical Trials Register (DRKS)
Iranian Registry of Clinical Trials (IRCT)
Japan Primary Registries Network (JPRN)
Thai Clinical Trials Registry (TCTR)
Pan African Clinical Trial Registry (PACTR)
Sri Lanka Clinical Trials Registry (SLCTR)
Upon submission, authors must provide the registration identification number and the URL for the trial's registry.
Authors can post their results in clinical trial registries as part of these requirements without it being considered previously published or overlapping publication.
Authors also must agree to submit the original protocol upon request from the editorial committee.
Prerequisites for publication
A copy of the certification form obtained from http://www.springer.com/12282 must be submitted to the journal’s editorial office by uploading it as a PDF file at the same time you submit your manuscript via Editorial Manager.
IMPORTANT: Upon receipt of Certification for Manuscript Submission , manuscripts are officially recognized as submissions.
Certification Form (Download pdf, 60 kB)
Permissions
Authors wishing to include figures, tables, or text passages that have already been published elsewhere are required to obtain permission from the copyright owner(s) for both the print and online format and to include evidence that such permission has been granted when submitting their papers. Any material received without such evidence will be assumed to originate from the authors.
Compliance with Ethical Standards
To ensure objectivity and transparency in research and to ensure that accepted principles of ethical and professional conduct have been followed, authors should include information regarding sources of funding, potential conflicts of interest (financial or non-financial), informed consent if the research involved human participants, and a statement on welfare of animals if the research involved animals.
Authors should include the following statements (if applicable) in a separate section entitled “Compliance with Ethical Standards” when submitting a paper:
· Disclosure of potential conflicts of interest
· Research involving Human Participants and/or Animals
· Informed consent
Please note that standards could vary slightly per journal dependent on their peer review policies (i.e. single or double blind peer review) as well as per journal subject discipline. Before submitting your article check the instructions following this section carefully.
The corresponding author should be prepared to collect documentation of compliance with ethical standards and send if requested during peer review or after publication.
The Editors reserve the right to reject manuscripts that do not comply with the above-mentioned guidelines. The author will be held responsible for false statements or failure to fulfill the above-mentioned guidelines.
Potential conflict of interest
All authors are required to disclose any financial relationship with a biotechnology manufacturer, pharmaceutical company, or other commercial entity that has an interest in the subject matter or materials discussed in the manuscript. Readers are entitled to transparency regarding any real or perceived conflicts of interest. This is not meant to imply that a financial relationship with an organization that sponsored the research or compensation received for consultancy work is necessarily inappropriate.
The corresponding author collects the conflict of interest disclosure forms from all authors. Further, the corresponding author includes a summary statement in the text of the manuscript in a separate section before the reference list, which reflects what is recorded in the potential conflict of interest disclosure form(s). See sample disclosures below:
A (author name) serves as a consultant to Z (entity name); B’s spouse is chairman of Y; C received a research grant from X; D received lecture fees from V; E holds a patent on U; F has been reimbursed by T for attending several conferences; G received honoraria for writing promotional material for S; H has no conflict of interest.
The “ICMJE Uniform Disclosure Form for Potential Conflicts of Interest” available at the ICMJE site ( http://www.icmje.org/) should be used.
Members of the Japanese Breast Cancer Society must also refer to the Breast Cancer Clinical Research Conflict of Interest Disclosure Policy and its regulations ( http://jbcs.gr.jp/english/conflict/).
ICMJE Uniform Disclosure Form for Potential Conflict of Interest
Conflict of Interest Form (Download pdf, 1.2 MB)
Research involving human participants and/or animals
1) Statement of human rights
When reporting studies that involve human participants, authors should include a statement that the studies have been approved by the appropriate institutional and/or national research ethics committee and have been performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.
If doubt exists whether the research was conducted in accordance with the 1964 Helsinki Declaration or comparable standards, the authors must explain the reasons for their approach, and demonstrate that the independent ethics committee or institutional review board explicitly approved the doubtful aspects of the study.
The following statements should be included in the text before the References section:
Ethical approval: “All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.”
For retrospective studies, please add the following sentence:
“For this type of study formal consent is not required.”
2) Statement on the welfare of animals
The welfare of animals used for research must be respected. When reporting experiments on animals, authors should indicate whether the international, national, and/or institutional guidelines for the care and use of animals have been followed, and that the studies have been approved by a research ethics committee at the institution or practice at which the studies were conducted (where such a committee exists).
For studies with animals, the following statement should be in the text before the References section:
Ethical approval: “All applicable international, national, and/or institutional guidelines for the care and use of animals were followed.”
If applicable (where such a committee exists): “All procedures performed in studies involving animals were in accordance with the ethical standards of the institution or practice at which the studies were conducted.”
If articles do not contain studies with human participants or animals by any of the authors, please select one of the following statements:
“This article does not contain any studies with human participants performed by any of the authors.”
“This article does not contain any studies with animals performed by any of the authors.”
“This article does not contain any studies with human participants or animals performed by any of the authors.”
……
更多详情：
https://www.springer.com/journal/12282/submission-guidelines
